China Biologic Receives $4.6 Billion Buyout Offer

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

TRENDING: Tech Brief (Sept. 22): Trump Says Murdoch Family May Be Involved in TikTok Deal

LATEST: Tech Brief (Sept. 22): Trump Says Murdoch Family May Be Involved in TikTok Deal; GPT Weekly: CoreWeave Secures $6.3 Billion Nvidia Order; Huawei Unveils Three-Year AI Chip Roadmap as Nvidia Faces Setbacks in China; Tencent Cloud Shuns Price War in Intensifying AI Race; China’s Regulator Ramps Up Push to Curb Food Delivery Subsidy War; Chinese Robot Startup Unitree Gears Up for Market Debut; China Enforces AI Content Labeling Rules to Curb Misuse; Tech Brief (Sept. 2): China Rolls Out Mandatory AI Labeling; Meituan Enters Open-Source AI Race With LongCat Model; Tech Brief (Aug. 29): SenseTime Reports Strong AI Growth; All Hail the Driverless Taxis as China Eyes a $183 Billion Market; Tech Brief (Aug. 27): Cambricon Reports $128 Million Profit, Stock More Than Doubles Since July; Tech Brief (Aug. 26): Musk’s xAI Sues Apple and OpenAI Over Alleged AI Market Monopoly; Exclusive: NetEase’s Youdao CEO Explains How AI Agents Could Build a Future of Virtual Teachers; Ant Group Teams up With Top Beijing Hospital to Launch AI Healthcare Lab; Didi and Meituan Clash in Brazil as Food Delivery Battle Goes to Court; Google Denies Rumors It Is Resuming Full Services on Chinese Mainland; China Proves a Winner in the Gaming Market as Growth Hits a Five-Year High; China’s Booster Robotics Lands New Funding as it Hits a Winning Streak; Amazon to Shut Down Shanghai AI Lab Amid Strategic Shift

By Matthew Walsh / Sep 19, 2019 02:27 PM / Business & Tech

Photo: VCG

Nasdaq-listed plasma-based biopharmaceutical company China Biologic Products has received a potential shot in the arm in the form of a $4.6 billion buyout offer, according to a Wednesday press release.

The offer price of $120 per share represents a 16.3% premium to China Biologic’s close of $103.10 on Wednesday.

The company, a leading provider of blood plasma-based therapies in China, received the proposal from a group of six buyers, including Beachhead Holdings and CITIC Capital China Partners, according to the release.

The offer is the second such proposal this week, after New York-listed Chinese car comparison website Bitauto received a similar proposal from internet giant Tencent and its private equity partner Hammer Capital.

Contact reporter Matthew Walsh (matthewwalsh@caixin.com)

Share this article

Open WeChat and scan the QR code